Exagen Inc. (XGN) 株式分析

企業概要

Exagen Inc. is an enterprise focused on the design, development, and commercialization of testing products under the AVISE brand within the United States, enabling healthcare providers to diagnose, prognose, and monitor complex rheumatic, autoimmune, and related diseases. The company operates within the Healthcare sector, specifically targeting the Diagnostics & Research industry, where it leverages technology to support patient care through advanced medical testing solutions. As of the latest reporting period, Exagen Inc. maintains a market capitalization of $74.08M and employs approximately 216 individuals across its operations. With annual revenue reaching $66.58M, the company demonstrates a mid-cap profile that suggests it has established a significant operational footprint while retaining the agility typical of smaller market participants in the specialized diagnostics space.

財務健全性

Exagen Inc. reported total revenue of $66.58M over the trailing twelve months, yet the company recorded a net income of -$19.95M and an EBITDA of -$11.95M. The substantial divergence between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and tax provisions significantly outweigh gross profits, resulting in a loss of nearly $20M despite generating over $66M in sales. The company generated free cash flow of -$10.36M, indicating that its cash outflows from operations and investing activities exceeded its cash inflows during the period, which constrains immediate financial flexibility and reliance on existing cash reserves. Margins across the board reflect this financial pressure, with a gross margin of 58.3% indicating efficient production or service delivery, contrasted sharply by an operating margin of -29.9% and a profit margin of -30.0% that highlight severe operating losses and net profitability challenges. The balance sheet shows a cash position of $32.22M against total debt of $27.67M, supported by a debt-to-equity ratio of 158.55, suggesting a leveraged capital structure where debt obligations exceed equity capitalization. Despite the leverage, the current ratio stands at 3.45, signaling a robust short-term liquidity position where current assets are more than three times current liabilities. Furthermore, the return on equity is -147.8% and the return on assets is -17.1%, metrics that indicate that management has not yet generated positive returns on the shareholders' investment or the total asset base, reflecting the ongoing nature of the business's developmental or loss-making phase.

バリュエーション評価

The valuation metrics for Exagen Inc. present a complex picture, with a trailing P/E ratio that is effectively N/A due to losses, while the forward P/E is listed at -9.94, implying that expected future earnings remain negative in the immediate projection horizon. The price-to-book ratio is 4.04, suggesting that the market values the company's equity at a significant premium of four times its book value, which often reflects investor expectations of future intangible asset appreciation or market share expansion. Additionally, the price-to-sales ratio of 1.11 and an EV/EBITDA of -5.82 provide alternative valuation lenses that price the business based on revenue generation and enterprise value relative to earnings power, rather than traditional profit multiples. The stock's trading range over the past year spans from a low of $2.59 to a high of $12.23, placing the current market price within this historical volatility band. The beta coefficient is recorded at 1.94, which indicates that the stock's price volatility is nearly double that of the broader market, exposing investors to substantial price swings relative to general market movements.

Growth & Income

Exagen Inc. demonstrated a year-over-year revenue growth rate of 21.8%, while the earnings growth rate is N/A due to the company's persistent net losses, meaning earnings are not growing faster than revenue but rather expanding from a negative baseline. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, as it currently reinvests all available capital back into its operations and product development rather than distributing income to shareholders. This non-dividend strategy aligns with the typical lifecycle of a company generating high revenue growth but lacking current profitability, prioritizing expansion over income distribution. Overall, the growth and income profile of Exagen Inc. is characterized by strong top-line expansion in the diagnostics sector coupled with significant operating losses and an absence of dividend income, reflecting a capital-intensive growth phase.